Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 2Recruiting 2Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

venetoclax 124Azacitidine 96Cytarabine 71fludarabine 44Specimen Handling 38Cyclophosphamide 38Daunorubicin 27Decitabine 26Biopsy 25Idarubicin 24Granulocyte Colony-Stimulating Factor 21gilteritinib 18Injections 18fludarabine phosphate 17Whole-Body Irradiation 17Melphalan 16Busulfan 16Stem Cell Transplantation 15Mycophenolic Acid 15ivosidenib 13Cladribine 13decitabine and cedazuridine drug combination 12Gemtuzumab 12Tacrolimus 11CPX-351 11X-Rays 10Filgrastim 10revumenib 9enasidenib 9Cyclosporine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myeloid, Acute × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Baylor College of Medicine

Phase EARLY_PHASE1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡